Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.
Two more ANDA companies have reached settlement agreements with AbbVie’s Allergan subsidiary and partner Pierre Fabre Medicament over proposed generic versions of the Fetzima serotonin and norepinephrine reuptake inhibitor.
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.
Lupin has agreed to pay $248m to settle the majority of antitrust claims against the company alleging that it caused and enabled the prolonged delayed launch of generic Glumetza, which subsequently saw a price hike of more than 800% by originator Valeant, now Bausch Health.
Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.
Regeneron Pharmaceuticals has spoken out on the implication of impending competition to Lucentis for its rival product Eylea, as the market for biosimilar Lucentis looks to form by the close of this year.